appliedtherapeutics.com - APLT Profit before deduction of interest, taxes, depreciation and amortization
The absolute cash result of operations demonstrates the efficiency of robotic molecule modeling for the therapy of rare pathologies for Applied Therapeutics (APLT). However, 0.00 captures the current state of the parameter against a backdrop of dependence on FDA verdicts and critical liquidity levels. Growth prospects are based on the market launch of the govorestat and the absence of competitors in narrow niches of metabolic medicine.
Summary analytical data breakdowns for Applied Therapeutics (APLT)
- stock value and consensus price forecast:
- issuer market value details:
- book capitalization indicators:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Applied Therapeutics|APLT - Long-Term Debt to Equity|Current Liabilities to Equity appliedtherapeutics.com|APLT - Company Aggregate Debts|Debt to Net Assets Ratio Applied Therapeutics|APLT - Company Long-Term Debts|Company Short-Term Debts Applied Therapeutics|Intermediate Coverage Ratio appliedtherapeutics.com
- earnings and market multiples details:
APLT - Company Net Income|Future Profit Applied Therapeutics|APLT - P/E Multiple|Forward P/E Multiple Applied Therapeutics Inc.|APLT - PEG Multiple|EV/EBITDA Multiple Applied Therapeutics|APLT - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Applied Therapeutics|APLT - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months appliedtherapeutics.com|APLT - Earnings per share growth in current year|Net earnings per share growth forecast for next year Applied Therapeutics
Summary company analytics:Applied Therapeutics Inc.
Applied Therapeutics' specialization in high-cost therapies for rare genetic pathologies establishes a foundation for high margins per product unit. The company's EBITDA dynamics reflect daily cash flow from core operations, eliminating the time gap between quarterly reports; meanwhile, the upward trend confirms operational resilience, while sharp peaks signal a risk of asset overvaluation.
Who Applied Therapeutics competes with
Operating income before deduction of amortization Vertex Corp (VRTX)|ALNY: Operating profit before deduction of amortization|Profit before deduction of interest, taxes, depreciation and amortization INSM|UTHR: Operating profit EBITDA|Profit before interest, taxes and amortization BioMarin Pharmaceutical Inc. (BMRN)|BBIO (BridgeBio Pharma Inc) - Operating profit EBITDA|Operating profit before amortization BGM (BGM Group Corp)|Operating profit before deduction of amortization COGT (Cogent Biosciences)|XERS (xerispharma.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Keros Therapeutics, Inc. KROS|ARCT (Arcturus Therapeutics Inc) - Profit before deduction of interest, taxes, depreciation and amortization|Eton Pharma - Operating profit EBITDA|Income before deduction of interest, taxes and amortization KMDA (Kamada Pharma)|FULC: Operating profit EBITDA|Abeona Therapeutics Inc. (ABEO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Mereo BioPharma Group|PLX: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Pliant Therapeutics (PLRX)|Operating profit before deduction of amortization Aileron Therapeutics RNTX|Operating profit EBITDA GELS (Gelteq)|Operating profit EBITDA Aytu BioPharma Inc AYTU|Chemomab - Operating profit EBITDA|SRXH - Operating profit EBITDA|polyrizon-biotech.com (PLRZ) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization AEZS (Aeterna Zentaris Inc.)|Profit before payment of interest, taxes and amortization Cyclo Therapeutics|Inozyme - Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Reneo Pharmaceuticals, Inc. (RPHM)|Profit before payment of interest, taxes and amortization CSCI (COSCIENS Biopharma Inc)
